Neumann F J, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schömig A
Deutsches Herzzentrum and 1. Medizinische Klinik der Technischen Universität München, Munich, Germany.
Circulation. 1998 Dec 15;98(24):2695-701. doi: 10.1161/01.cir.98.24.2695.
Apart from its established effects on vessel patency after percutaneous coronary revascularization, glycoprotein IIb/IIIa receptor blockade by abciximab may improve myocardial perfusion by inhibition of the interaction of platelets and platelet aggregates with the microvasculature. We investigated the effect of abciximab with stent placement in acute myocardial infarction.
In a prospective randomized trial, patients undergoing stenting in acute myocardial infarction within 48 hours after onset of symptoms were randomly assigned to receive either standard-dose heparin or abciximab plus low-dose heparin. Immediately after the procedure and at 14-day angiographic follow-up, we assessed flow velocity in the recanalized vessel with the Doppler wire and regional wall motion by the centerline method. End points were changes in papaverine-induced peak flow velocities and in wall motion indices. We assigned 98 patients to standard heparin and 102 to abciximab. We obtained 152 paired flow measurements and 151 paired left ventricular function studies. Residual stenoses of the treated lesions did not differ between the 2 groups. Improvement of peak flow velocity (mean [95% CI]: 18.1 cm/s [13.6 to 22.6 cm/s], n=80, versus 10.4 cm/s [5.4 to 15.4 cm/s], n=72, P=0.024) and wall motion index (0.44 SD/chord [0.29 to 0.59 SD/chord], n=79 versus 0. 15 SD/chord [0.00 to 0.30 SD/chord], n=72, P=0.007) was significantly greater in patients assigned to abciximab than in those on heparin alone. At follow-up, the abciximab group had a higher global left ventricular ejection fraction than the heparin group (62% [59% to 65%] versus 56% [53% to 59%], P=0.003).
Abciximab had important effects beyond the maintenance of large-vessel patency. It improved the recovery of microvascular perfusion and concomitantly enhanced the recovery of contractile function in the area at risk.
除了其在经皮冠状动脉血运重建术后对血管通畅性的既定作用外,阿昔单抗对糖蛋白IIb/IIIa受体的阻滞作用可能通过抑制血小板及血小板聚集体与微血管系统的相互作用来改善心肌灌注。我们研究了阿昔单抗联合支架置入术在急性心肌梗死中的作用。
在一项前瞻性随机试验中,将症状发作后48小时内行急性心肌梗死支架置入术的患者随机分为两组,分别接受标准剂量肝素或阿昔单抗加小剂量肝素治疗。术后即刻及14天血管造影随访时,我们用多普勒导丝评估再通血管的血流速度,并用中心线法评估局部室壁运动。终点指标为罂粟碱诱导的峰值血流速度及室壁运动指数的变化。我们将98例患者分配至标准肝素组,102例分配至阿昔单抗组。我们获得了152对血流测量值及151对左心室功能研究数据。两组治疗病变的残余狭窄程度无差异。阿昔单抗组患者的峰值血流速度改善情况(均值[95%可信区间]:18.1 cm/s[13.6至22.6 cm/s],n = 80,对比10.4 cm/s[5.4至15.4 cm/s],n = 72,P = 0.024)及室壁运动指数(0.44 SD/弦[0.29至0.59 SD/弦],n = 79对比0.15 SD/弦[0.00至0.30 SD/弦],n = 72,P = 0.007)显著优于单纯肝素组患者。随访时,阿昔单抗组的整体左心室射血分数高于肝素组(62%[59%至65%]对比56%[53%至59%],P = 0.003)。
阿昔单抗除了维持大血管通畅外还有重要作用。它改善了微血管灌注的恢复,并同时增强了梗死危险区域收缩功能的恢复。